Association of Hyperuricemia With Immune Disorders and Intestinal Barrier Dysfunction

BackgroundMore than 30–40% of uric acid is excreted via the intestine, and the dysfunction of intestinal epithelium disrupts uric acid excretion. The involvement of gut microbiota in hyperuricemia has been reported in previous studies, but the changes and mechanisms of intestinal immunity in hyperur...

Full description

Bibliographic Details
Main Authors: Qiulan Lv, Daxing Xu, Xuezhi Zhang, Xiaomin Yang, Peng Zhao, Xuena Cui, Xiu Liu, Wan Yang, Guanpin Yang, Shichao Xing
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Physiology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphys.2020.524236/full
id doaj-7d644b67f4034d018c73e65fec6dcc60
record_format Article
spelling doaj-7d644b67f4034d018c73e65fec6dcc602020-12-08T08:40:59ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2020-11-011110.3389/fphys.2020.524236524236Association of Hyperuricemia With Immune Disorders and Intestinal Barrier DysfunctionQiulan Lv0Daxing Xu1Xuezhi Zhang2Xiaomin Yang3Peng Zhao4Xuena Cui5Xiu Liu6Wan Yang7Guanpin Yang8Shichao Xing9Shichao Xing10Shichao Xing11Medical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaMedical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaMedical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaMedical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaMedical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaMedical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaMedical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaMedical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaThe Key Laboratory of Mariculture, Ministry of Education, Ocean University of China, Qingdao, ChinaMedical Research Center, Affiliated Hospital of Qingdao University, Qingdao, ChinaInstitute of Sports Medicine and Health, Qingdao University, Qingdao, ChinaGuy’s & St Thomas’ Hospital, King’s College London, London, United KingdomBackgroundMore than 30–40% of uric acid is excreted via the intestine, and the dysfunction of intestinal epithelium disrupts uric acid excretion. The involvement of gut microbiota in hyperuricemia has been reported in previous studies, but the changes and mechanisms of intestinal immunity in hyperuricemia are still unknown.MethodsThis study developed a urate oxidase (Uox)-knockout (Uox–/–) mouse model for hyperuricemia using CRISPR/Cas9 technology. The lipometabolism was assessed by measuring changes in biochemical indicators. Furthermore, 4-kDa fluorescein isothiocyanate–labeled dextran was used to assess gut barrier function. Also, 16S rRNA sequencing was performed to examine the changes in gut microbiota in mouse feces. RNA sequencing, Western blot, Q-PCR, ELISA, and immunohistochemical analysis were used for measuring gene transcription, the number of immune cells, and the levels of cytokines in intestinal tissues, serum, kidney, liver, pancreas, and vascellum.ResultsThis study showed that the abundance of inflammation-related microbiota increased in hyperuricemic mice. The microbial pattern recognition–associated Toll-like receptor pathway and inflammation-associated TNF and NF-kappa B signaling pathways were significantly enriched. The increased abundance of inflammation-related microbiota resulted in immune disorders and intestinal barrier dysfunction by upregulating TLR2/4/5 and promoting the release of IL-1β and TNF-α. The levels of epithelial tight junction proteins occludin and claudin-1 decreased. The expression of the pro-apoptotic gene Bax increased. The levels of LPS and TNF-α in systemic circulation increased in hyperuricemic mice. A positive correlation was observed between the increase in intestinal permeability and serum levels of uric acid.ConclusionHyperuricemia was characterized by dysregulated intestinal immunity, compromised intestinal barrier, and systemic inflammation. These findings might serve as a basis for future novel therapeutic interventions for hyperuricemia.https://www.frontiersin.org/articles/10.3389/fphys.2020.524236/fullhyperuricemiagut microbiotaintestinal immuneintestinal barriersystem inflammation
collection DOAJ
language English
format Article
sources DOAJ
author Qiulan Lv
Daxing Xu
Xuezhi Zhang
Xiaomin Yang
Peng Zhao
Xuena Cui
Xiu Liu
Wan Yang
Guanpin Yang
Shichao Xing
Shichao Xing
Shichao Xing
spellingShingle Qiulan Lv
Daxing Xu
Xuezhi Zhang
Xiaomin Yang
Peng Zhao
Xuena Cui
Xiu Liu
Wan Yang
Guanpin Yang
Shichao Xing
Shichao Xing
Shichao Xing
Association of Hyperuricemia With Immune Disorders and Intestinal Barrier Dysfunction
Frontiers in Physiology
hyperuricemia
gut microbiota
intestinal immune
intestinal barrier
system inflammation
author_facet Qiulan Lv
Daxing Xu
Xuezhi Zhang
Xiaomin Yang
Peng Zhao
Xuena Cui
Xiu Liu
Wan Yang
Guanpin Yang
Shichao Xing
Shichao Xing
Shichao Xing
author_sort Qiulan Lv
title Association of Hyperuricemia With Immune Disorders and Intestinal Barrier Dysfunction
title_short Association of Hyperuricemia With Immune Disorders and Intestinal Barrier Dysfunction
title_full Association of Hyperuricemia With Immune Disorders and Intestinal Barrier Dysfunction
title_fullStr Association of Hyperuricemia With Immune Disorders and Intestinal Barrier Dysfunction
title_full_unstemmed Association of Hyperuricemia With Immune Disorders and Intestinal Barrier Dysfunction
title_sort association of hyperuricemia with immune disorders and intestinal barrier dysfunction
publisher Frontiers Media S.A.
series Frontiers in Physiology
issn 1664-042X
publishDate 2020-11-01
description BackgroundMore than 30–40% of uric acid is excreted via the intestine, and the dysfunction of intestinal epithelium disrupts uric acid excretion. The involvement of gut microbiota in hyperuricemia has been reported in previous studies, but the changes and mechanisms of intestinal immunity in hyperuricemia are still unknown.MethodsThis study developed a urate oxidase (Uox)-knockout (Uox–/–) mouse model for hyperuricemia using CRISPR/Cas9 technology. The lipometabolism was assessed by measuring changes in biochemical indicators. Furthermore, 4-kDa fluorescein isothiocyanate–labeled dextran was used to assess gut barrier function. Also, 16S rRNA sequencing was performed to examine the changes in gut microbiota in mouse feces. RNA sequencing, Western blot, Q-PCR, ELISA, and immunohistochemical analysis were used for measuring gene transcription, the number of immune cells, and the levels of cytokines in intestinal tissues, serum, kidney, liver, pancreas, and vascellum.ResultsThis study showed that the abundance of inflammation-related microbiota increased in hyperuricemic mice. The microbial pattern recognition–associated Toll-like receptor pathway and inflammation-associated TNF and NF-kappa B signaling pathways were significantly enriched. The increased abundance of inflammation-related microbiota resulted in immune disorders and intestinal barrier dysfunction by upregulating TLR2/4/5 and promoting the release of IL-1β and TNF-α. The levels of epithelial tight junction proteins occludin and claudin-1 decreased. The expression of the pro-apoptotic gene Bax increased. The levels of LPS and TNF-α in systemic circulation increased in hyperuricemic mice. A positive correlation was observed between the increase in intestinal permeability and serum levels of uric acid.ConclusionHyperuricemia was characterized by dysregulated intestinal immunity, compromised intestinal barrier, and systemic inflammation. These findings might serve as a basis for future novel therapeutic interventions for hyperuricemia.
topic hyperuricemia
gut microbiota
intestinal immune
intestinal barrier
system inflammation
url https://www.frontiersin.org/articles/10.3389/fphys.2020.524236/full
work_keys_str_mv AT qiulanlv associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction
AT daxingxu associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction
AT xuezhizhang associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction
AT xiaominyang associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction
AT pengzhao associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction
AT xuenacui associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction
AT xiuliu associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction
AT wanyang associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction
AT guanpinyang associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction
AT shichaoxing associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction
AT shichaoxing associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction
AT shichaoxing associationofhyperuricemiawithimmunedisordersandintestinalbarrierdysfunction
_version_ 1724390415537274880